AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.16
-0.10 (-7.94%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.26
Open1.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.15 - 1.87
52 Week Range1.15 - 19.60
Volume1,823,312
Avg. Volume151,347
Market Cap5.765M
Beta2.58
PE Ratio (TTM)N/A
EPS (TTM)-12.76
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire19 hours ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S.  Robust Natesto prescription growth continued through January 2018, with total prescriptions reaching 1,094, their highest level to date and demonstrating 300% growth over the same month last year.  Additionally, for the three months ending January 31, 2018 Natesto prescriptions increased 12% over the three-month period ending October 31, 2017. Natesto total prescriptions for the month of January were 1,094, the highest monthly total recorded to date.

  • Benzinga6 days ago

    Moleculin Biotech's Volatility, Explained

    Moleculin Biotech Inc (NASDAQ: MBRX )’s good-news rally had a short life. The stock popped 55 percent Thursday after management announced a “breakthrough” discovery of a molecule capable of shutting down ...

  • Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswire13 days ago

    Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last year ENGLEWOOD, Colo. , Feb. 8, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life ...

  • Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update
    PR Newswire21 days ago

    Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Feb. 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal second quarter 2018 on Thursday, February 8, 2018, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswirelast month

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , Jan. 16, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2017 performance ...

  • Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?
    Simply Wall St.2 months ago

    Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?

    Aytu BioScience Inc (NASDAQ:AYTU), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AYTURead More...

  • Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference
    PR Newswire2 months ago

    Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference

    Aytu's management will present on Tuesday, January 9th at 9:30 AM PT in Yosemite-C (Ballroom level) and will be meeting with investors throughout the conference. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

  • PR Newswire2 months ago

    Aytu BioScience Announces Appointment of David Green as Chief Financial Officer

    ENGLEWOOD, Colo., Dec. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the appointment of David A. Green as Chief Financial Officer.  Mr. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu, including a background at both public and private life sciences companies over his twenty-five-year career.  Effective today Mr. Green joins Aytu BioScience to oversee the Company's finance and accounting functions, and will report directly to the Chief Executive Officer. Prior to joining Aytu BioScience, Mr. Green served as Chief Accounting Officer at Intarcia Therapeutics, a biopharmaceutical company currently engaged in late stage clinical development.  Prior to that, he was Chief Financial Officer of Catheter Connections, a commercial-stage medical device company that was acquired by Merit Medical.

  • Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.3 months ago

    Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?

    Measuring Aytu BioScience Inc’s (NASDAQ:AYTU) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE3 months ago

    Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 29, 201 7 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, ...

  • Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017
    Capital Cube3 months ago

    Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Aytu BioScience, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aytu BioScience, Inc. – Career Education Corporation, Capella Education Company and Cambium Learning Group, Inc. (CECO-US, CPLA-US and ABCD-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire3 months ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Nov. 28, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the launch of Natesto in the U.S.  Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.  Additionally, in October, the number of physicians prescribing Natesto increased 16% from the previous month.

  • Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswire3 months ago

    Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    ENGLEWOOD, Colo. , Nov. 9, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility
    PR Newswire4 months ago

    Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility

    ENGLEWOOD, Colo., Nov. 7, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Australian Government Department of Health and Therapeutic Goods Administration (TGA) has approved the MiOXSYS® System for inclusion on the Australian Register of Therapeutic Goods. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "MiOXSYS continues to gain traction with its international commercial expansion as regulatory bodies, like Australia's TGA, approve the product for clinical use in the assessment of male infertility. In Australia, approximately one in six couples suffer from infertility, and almost half of these cases can be attributed to male factor infertility.

  • Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update
    PR Newswire4 months ago

    Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Nov. 2, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal first quarter 2018 on Thursday, November 9, 2017, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine
    PR Newswire4 months ago

    Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine

    ENGLEWOOD, Colo. , Nov. 1, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Provides Quarterly Update on the Natesto® U.S. Launch
    PR Newswire4 months ago

    Aytu BioScience Provides Quarterly Update on the Natesto® U.S. Launch

    ENGLEWOOD, Colo. , Oct. 26, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience to Ring The NASDAQ Closing Bell Friday, October 20, 2017
    PR Newswire4 months ago

    Aytu BioScience to Ring The NASDAQ Closing Bell Friday, October 20, 2017

    ENGLEWOOD, Colo., Oct. 19, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will ring the NASDAQ closing bell on Friday, October 20, 2017 at 4:00 p.m. EDT. The bell ringing will celebrate the Company's recent accomplishments and listing on The NASDAQ Capital Market. The Company was approved for listing and begins trading on The NASDAQ Capital Market on Friday, October 20th under the company's current ticker symbol, AYTU.

  • Aytu BioScience Announces Uplisting to The NASDAQ Capital Market
    PR Newswire4 months ago

    Aytu BioScience Announces Uplisting to The NASDAQ Capital Market

    ENGLEWOOD, Colo. , Oct. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • CNW Group4 months ago

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

  • PR Newswire4 months ago

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

    Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation ENGLEWOOD, Colo. , Oct. 9, 2017 /PRNewswire/ --  Aytu BioScience ...

  • Aytu BioScience Announces International Distribution Agreement for Fiera® in Japan
    PR Newswire5 months ago

    Aytu BioScience Announces International Distribution Agreement for Fiera® in Japan

    ENGLEWOOD, Colo., Oct. 3, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the company has entered into a distribution agreement with Mitsuboshi Product Planning Ltd to market and distribute Fiera in Japan.  Mitsuboshi is a specialty life sciences company engaged in the research, development and commercialization of products related to infertility and female sexual wellness.  Mitsuboshi is the company's first international distributor of Fiera, and the company expects to announce additional international distribution partnerships for Fiera in the future. Up to 9 million Japanese women express one or more sexual concerns.  The Japanese sexual wellness market has been estimated at over $270 million annually.

  • Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017
    Capital Cube5 months ago

    Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Aytu BioScience, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 0.84 million, Net Earnings of USD -3.04 million. Gross margins narrowed from 23.73% to -193.15% compared to the same period last year, operating (EBITDA) margins now 32.66% from -571.71%. Change in operating ... Read more (Read more...)

  • CNW Group5 months ago

    Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th

    Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th